Physician profile
Jeffrey B Glaser
NPI 1154357010
$164,540.42
in general payments reported to CMS, 2019-2025
38 companies · $7,784 in 2025
The $7,784 reported for 2025 was more than what 95% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,888 · 2020: $19K · 2021: $36K · 2022: $45K · 2023: $36K · 2024: $14K · 2025: $7,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $15K · Food and Beverage: $9,195 · Travel and Lodging: $6,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,073.76 |
| Consulting Fee | $15,040.00 |
| Food and Beverage | $9,195.12 |
| Travel and Lodging | $6,976.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $64,416.86 | 2021-2025 | |
| Abbott Laboratories | $49,333.78 | 2019-2025 | Proclaim, Eterna, Octrode |
| Allergan, INC. | $18,341.91 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $10,838.74 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $6,419.65 | 2022 | |
| Boston Scientific Corporation | $6,077.49 | 2019-2025 | Intracept, General - Pain Management, Compliance Endokit |
| Nevro Corp. | $3,371.62 | 2019-2022 | |
| Vertiflex, INC. | $1,806.00 | 2019 | |
| Nalu Medical, INC. | $1,195.44 | 2024-2025 | Nalu Neurostimulation System |
| Globus Medical, INC. | $487.57 | 2025 | Senza, Omnia |
| Biotronik Nro, INC. | $250.89 | 2023-2025 | Prospera, Biotronik |
| Horizon Therapeutics Plc | $199.88 | 2019-2020 | |
| Axsome Therapeutics, INC. | $199.71 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $167.09 | 2019-2020 | |
| Lilly USA, LLC | $133.46 | 2019-2024 | Emgality, Reyvow |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $105.15 | 2019-2023 | Ztlido |
| Pfizer INC. | $102.90 | 2019-2023 | |
| Stryker Corporation | $98.94 | 2019-2021 | |
| Spinesmith Holdings, LLC | $82.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $81.75 | 2019-2020 | |
| Redhill Biopharma INC. | $77.48 | 2020-2021 | |
| Intersect Ent, INC. | $74.47 | 2019 | |
| Assertio Therapeutics, INC. | $67.56 | 2019-2020 | |
| Medtronic USA, INC. | $63.17 | 2020 | |
| Amgen INC. | $62.92 | 2020-2021 | |
| Relievant Medsystems, INC. | $60.35 | 2021-2023 | Intracept |
| Zyla Life Sciences, INC. | $50.55 | 2019 | |
| Stimwave Technologies Incorporated | $48.21 | 2019 | |
| Djo, LLC | $46.96 | 2024 | Aircast |
| Azurity Pharmaceuticals, INC. | $45.54 | 2023-2024 | Horizant, Horizant |
| Bioventus LLC | $45.28 | 2022 | |
| Forte Bio-Pharma LLC | $43.25 | 2021 | |
| Shionogi INC | $33.77 | 2019 | |
| Ibsa Pharma INC. | $33.50 | 2021-2023 | Tirosint, Licart |
| Impel Pharmaceuticals INC. | $21.85 | 2023 | Trudhesa |
| Almatica Pharma LLC | $21.19 | 2021 | |
| Spr Therapeutics, INC | $18.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Glaser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.